GeoVax, Inc. HIV/AIDS [HIV-1] Vaccines, initially developed by Dr. Harriet Robinson [GeoVax Scientific Advisory Board Chairperson] at Emory University in collaboration with researchers at the NIAID (NIH), and the USA Centers for Disease Control (CDC), are recombinant DNA and MVA vaccines. Our focus is on developing AIDS vaccines comprising the major HIV-1 subtypes (A, B and C). These vaccines will be able to be used alone or as combinations depending on a local infection. Subtype B is most common in North America, the EU, Japan and Australia and is our first priority.
When administered in series, these AIDS vaccines induce strong cellular and humoral immunity [protection] in non human primates against multiple HIV-1 proteins [AIDS virus components]. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people.